

## EDITORIALS



## Clinical Credence — SGLT2 Inhibitors, Diabetes, and Chronic Kidney Disease

Julie R. Ingelfinger, M.D., and Clifford J. Rosen, M.D.

The number of people who die from kidney disease every year has risen over the past decade and is now estimated at 5 million to 10 million worldwide. The increase in rates of obesity — along with associated rates of type 2 diabetes, hypertension, and cardiovascular disease — has principally driven the elevated mortality. More than 660,000 Americans have reached the point of requiring intervention for end-stage kidney disease, with 468,000 receiving dialysis and more than 193,000 undergoing kidney transplantation, leading to a major public health and economic burden.<sup>1</sup> Hence, the development of new treatments that may prevent or delay the progression of chronic kidney disease, as well as treat type 2 diabetes, is an important goal.

Tight control of glucose levels and blood pressure slows but does not prevent the onset of diabetic nephropathy.<sup>2</sup> The standard approach for retarding the onset of diabetic nephropathy and stabilizing renal function has been blockade of the renin–angiotensin–aldosterone system, particularly with inhibitors of angiotensin-converting enzyme. This approach was first used in the early 1990s in patients with type 1 diabetes<sup>3</sup>; randomized trials subsequently established that such drugs were also effective in type 2 diabetes.<sup>4</sup> Newer classes of agents have also been tried but have not been successful.

Inhibitors of sodium–glucose cotransporter-2 (SGLT2) were initially approved as a new class of hypoglycemic agents that lowered blood glucose levels in patients with type 2 diabetes by enhancing urinary glucose excretion through the inhibition of SGLT2 in the proximal convoluted

tubule, where glucose is reabsorbed. SGLT2 inhibitors reduce the renal threshold of glucose from 180 mg per deciliter (10 mmol per liter) to 40 to 120 mg per deciliter (2 to 7 mmol per liter), thereby effectively lowering blood glucose levels. In 2015, EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients)<sup>5</sup> changed the landscape in diabetes management by showing a lower risk of cardiovascular death among the 4687 patients who received empagliflozin than among the 2333 controls (172 patients [3.7%] vs. 137 patients [5.9%]) (hazard ratio, 0.62; 95% confidence interval [CI], 0.49 to 0.77). Patients in the empagliflozin group also had a lower risk of death from any cause (269 patients [5.7%] vs. 194 patients [8.3%]) (hazard ratio, 0.68; 95% CI, 0.57 to 0.82) and a lower risk of hospitalization for heart failure (126 patients [2.7%] vs. 95 patients [4.1%]) (hazard ratio, 0.65; 95% CI, 0.50 to 0.85). Recently, the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)<sup>6</sup> showed similar cardiovascular benefits, indicating a class effect of SGLT2 inhibitors. Further support for that finding was noted in the CVD-REAL (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors)<sup>7</sup> and the Health Improvement Network (THIN) trials.<sup>8</sup> As a result, SGLT2 inhibitors are now widely used in patients with type 2 diabetes both to improve glycated hemoglobin levels and to reduce cardiovascular risk.

Recent studies have hinted that medications designed to treat diabetes could also confer renoprotection through a mechanism that differs

from those affecting glucose homeostasis.<sup>3,4,7</sup> Among these drugs, the SGLT2 inhibitors appeared to be the most promising.

In the *Journal*, Perkovic et al.<sup>9</sup> now report the primary results of the double-blind, randomized CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial, in which 4401 patients with type 2 diabetes and albuminuric chronic kidney disease received 100 mg of canagliflozin or placebo added to renin-angiotensin-aldosterone blockade and baseline diabetic therapy after a 2-week run-in period. All the participants met the criteria of having an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m<sup>2</sup> of body-surface area and a urinary albumin-to-creatinine ratio of more than 300 (with albumin measured in milligrams and creatinine in grams). Sixty percent of the patients had an estimated GFR of 30 to 60 ml per minute per 1.73 m<sup>2</sup>. The primary outcome was a composite of end-stage kidney disease (dialysis for at least 30 days, transplantation, or a sustained estimated GFR of less than 15 ml per minute per 1.73 m<sup>2</sup> for 30 days), doubling of the serum creatinine level for at least 30 days, or death from renal or cardiovascular disease. Secondary outcomes included cardiovascular outcomes (death, heart failure, myocardial infarction, or stroke). The trial was halted early (median follow-up, 2.62 years) after a planned interim analysis indicated that the primary outcome had been met.

The relative risk of the primary outcome was nearly 30% lower in the canagliflozin group than in the placebo group. There was also a 20 to 30% lower relative risk of deleterious cardiovascular outcomes. The glycated hemoglobin levels were reduced more by canagliflozin than by placebo, as were blood pressure and body weight. The slope of the decline in the estimated GFR was slower in the canagliflozin group than in the placebo group. Rates of two targeted adverse events, fractures and lower-limb amputations, were similar in the two groups; diabetic ketoacidosis was more frequent in the canagliflozin group than in the placebo group, despite the overall low rates (2.2 vs. 0.2 per 1000 patient-years).

The underlying mechanisms of canagliflozin activity are probably both renal and systemic. SGLT2 inhibition increases glucose and sodium

delivery to the distal renal tubule, which is sensed by the juxtaglomerular apparatus as increased glomerular perfusion. This leads to increased vasoconstriction of the afferent arteriole, which decreases glomerular perfusion and intraglomerular pressure. Although these effects decrease the estimated GFR in the short term, as was seen during the first weeks of the CREDENCE trial, over time that effect stabilizes. The level of angiotensin II in the circulation decreases, as does the level of atrial natriuretic peptide, with a subsequent decrease in inflammation and an increase in intrarenal oxygenation. Decreased body weight and sympathetic output, decreased uric acid, and perhaps an increase in glucagon may also contribute.<sup>10</sup> Other hypoglycemic agents, such as inhibitors of dipeptidyl peptidase-4, also suppress oxidative stress, lessening fibrosis and apoptosis, which may retard progression.<sup>4</sup>

Overall, the importance of CREDENCE,<sup>9</sup> a well done and large clinical trial, cannot be overstated. The investigators estimated that among 1000 patients treated for 2.5 years, 22 would need to be treated with canagliflozin to prevent the composite primary outcome of end-stage kidney disease, doubling of the serum creatinine level, or renal or cardiovascular death. In addition, among the same number of patients, canagliflozin treatment would prevent 22 hospitalizations for heart failure and 25 composite events of cardiovascular death, myocardial infarction, or stroke. Such data are certain to be welcomed by patients with diabetes and chronic kidney disease and by the clinicians who treat them.

Disclosure forms provided by the authors are available with the full text of this editorial at NEJM.org.

From the Tufts University School of Medicine, Boston, and the Center for Clinical and Translational Research, Maine Medical Center Research Institute, Scarborough (C.J.R.).

This editorial was published on April 14, 2019, at NEJM.org.

1. National Kidney Foundation. End stage renal disease in the United States, 2019 (<https://www.kidney.org/news/newsroom/factsheets/End-Stage-Renal-Disease-in-the-US>).
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998;352:837-53.
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. *N Engl J Med* 1993;329:1456-62.

4. Umanath K, Lewis JB. Update on diabetic nephropathy: core curriculum 2018. *Am J Kidney Dis* 2018;71:884-95.
5. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med* 2015;373:2117-28.
6. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med* 2017;377:644-57.
7. Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). *Circulation* 2017;136:249-59.
8. Toulis KA, Willis BH, Marshall T, et al. All-cause mortality in patients with diabetes under treatment with dapagliflozin: a population-based, open-cohort study in The Health Improvement Network database. *J Clin Endocrinol Metab* 2017;102:1719-25.
9. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med* 2019;380:2295-306.
10. Tsimihodimos V, Filippatos TD, Elisaf MS. SGLT2 inhibitors and the kidney: Effects and mechanisms. *Diabetes Metab Syndr* 2018;12:1117-23.

DOI: 10.1056/NEJMe1904740

Copyright © 2019 Massachusetts Medical Society.

---



---

## Oligonucleotide Treatment for Huntington's Disease

Kenneth H. Fischbeck, M.D., and Nancy S. Wexler, Ph.D.

Huntington's disease is a severe autosomal-dominant neurodegenerative disorder that involves chorea, cognitive decline, and psychological problems such as depression, delusions, and impulsive behavior. Nowhere are the manifestations more striking than around Lake Maracaibo in northwestern Venezuela, where the disease is almost epidemic. The Huntington's disease kindreds in Venezuela encompass more than 18,000 persons spanning 10 generations. DNA samples from nearly 4000 patients and family members in this area were used to map the Huntington's gene to chromosome 4 in 1983<sup>1</sup> and to identify the disease gene in 1993.<sup>2</sup> Subsequent studies in this population have discovered modifiers of age at onset.<sup>3</sup> A new prospective treatment specifically targeting the messenger RNA (mRNA) encoding the mutant protein has been tested in patients with Huntington's disease, as now reported in the *Journal* by Tabrizi et al.<sup>4</sup>

Huntington's disease is caused by a trinucleotide repeat expansion that results in an expanded polyglutamine tract in the disease protein, huntingtin. The mutant protein is toxic and prone to aggregation in cell culture, animal models, and human brains. Remarkably, disease manifestations are reversed when the mutant gene is turned off or suppressed in transgenic mice,<sup>5,6</sup> which suggests that this approach could be effective in humans. Oligonucleotides targeting mutant huntingtin mRNA for degradation did not result in adverse effects when delivered intrathecally in nonhuman primates, and they reduced hunting-

tin levels throughout the brain.<sup>6</sup> Although complete loss of normal huntingtin results in embryonic lethality in mice,<sup>7</sup> partial reduction in levels later in life has an acceptable safety profile. This allows a non-allele-specific approach, in which the treatment would be suitable for all patients. Importantly, the levels of huntingtin protein can be assessed in the spinal fluid and correlate well with levels in the brain, thus providing a measure of the biologic effect of the treatment.

The trial reported by Tabrizi et al. involved 46 patients who were randomly assigned to receive placebo or one of five doses of the oligonucleotide HTT<sub>Rx</sub> and followed at nine centers in the United Kingdom, Germany, and Canada. The patients received four injections into the spinal fluid at 4-week intervals, with a 4-month follow-up. The trial agent was not associated with dose-limiting adverse events; the most common adverse effects were related to the lumbar punctures. There was a dose-dependent increase in the concentration of HTT<sub>Rx</sub> and a decrease in levels of mutant huntingtin protein in the spinal fluid. Remarkably, the reduction in the levels of mutant huntingtin was in a range that is expected to have therapeutic benefit on the basis of studies in animals. This is a pathbreaking trial that strongly supports further development of HTT<sub>Rx</sub> as a treatment for Huntington's disease. A confirmatory phase 3 trial is now under way (ClinicalTrials.gov number, NCT03761849), with a plan to follow 660 patients worldwide for up to 2 years. Now, 26 years after the discovery of the etiologic